Cargando…

Aerosol risk with noninvasive respiratory support in patients with COVID‐19

OBJECTIVES: This study evaluates aerosol production with high‐flow nasal cannula (HFNC) and noninvasive positive pressure ventilation (NIPPV) compared to 6 L/min by low‐flow nasal cannula. METHODS: Two healthy volunteers were randomized to control (6 L/min by low‐flow nasal cannula), NIPPV, or HFNC...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, David C., Beamer, Paloma, Billheimer, Dean, Subbian, Vignesh, Sorooshian, Armin, Campbell, Beth Salvagio, Mosier, Jarrod M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280651/
https://www.ncbi.nlm.nih.gov/pubmed/32838370
http://dx.doi.org/10.1002/emp2.12152
_version_ 1783543770817495040
author Miller, David C.
Beamer, Paloma
Billheimer, Dean
Subbian, Vignesh
Sorooshian, Armin
Campbell, Beth Salvagio
Mosier, Jarrod M.
author_facet Miller, David C.
Beamer, Paloma
Billheimer, Dean
Subbian, Vignesh
Sorooshian, Armin
Campbell, Beth Salvagio
Mosier, Jarrod M.
author_sort Miller, David C.
collection PubMed
description OBJECTIVES: This study evaluates aerosol production with high‐flow nasal cannula (HFNC) and noninvasive positive pressure ventilation (NIPPV) compared to 6 L/min by low‐flow nasal cannula. METHODS: Two healthy volunteers were randomized to control (6 L/min by low‐flow nasal cannula), NIPPV, or HFNC using block randomization. NIPPV conditions were studied using continuous positive airway pressures of 5, 10, and 15 cm H(2)O with an FiO(2) of 1.0 delivered via full‐face mask. HFNC conditions included flow rates of 30 and 40 L/min with an FiO(2) of 1.0 with and without coughing. HFNC and low‐flow nasal cannula conditions were repeated with and without participants wearing a surgical mask. Six aerosol sizes (0.3, 1.0, 2.5, 5, and 10 µm) and total aerosol mass were measured at 2 and 6 ft from the participant's nasopharynx. RESULTS: There was no significant difference in aerosol production between either HFNC or NIPPV and control. There was also no significant difference with the use of a procedural mask over the HFNC. There was significant variation between the 2 participants, but in neither case was there a difference compared to control. There was an aerosol‐time trend, but there does not appear to be a difference between either flow rate, pressure, or control. Furthermore, there was no accumulation of total aerosol particles over the total duration of the experiment in both HFNC and NIPPV conditions. CONCLUSIONS: HFNC and NIPPV did not increase aerosol production compared to 6 L/min by low‐flow nasal cannula in this experiment involving healthy volunteers.
format Online
Article
Text
id pubmed-7280651
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72806512020-06-09 Aerosol risk with noninvasive respiratory support in patients with COVID‐19 Miller, David C. Beamer, Paloma Billheimer, Dean Subbian, Vignesh Sorooshian, Armin Campbell, Beth Salvagio Mosier, Jarrod M. J Am Coll Emerg Physicians Open Infectious Disease OBJECTIVES: This study evaluates aerosol production with high‐flow nasal cannula (HFNC) and noninvasive positive pressure ventilation (NIPPV) compared to 6 L/min by low‐flow nasal cannula. METHODS: Two healthy volunteers were randomized to control (6 L/min by low‐flow nasal cannula), NIPPV, or HFNC using block randomization. NIPPV conditions were studied using continuous positive airway pressures of 5, 10, and 15 cm H(2)O with an FiO(2) of 1.0 delivered via full‐face mask. HFNC conditions included flow rates of 30 and 40 L/min with an FiO(2) of 1.0 with and without coughing. HFNC and low‐flow nasal cannula conditions were repeated with and without participants wearing a surgical mask. Six aerosol sizes (0.3, 1.0, 2.5, 5, and 10 µm) and total aerosol mass were measured at 2 and 6 ft from the participant's nasopharynx. RESULTS: There was no significant difference in aerosol production between either HFNC or NIPPV and control. There was also no significant difference with the use of a procedural mask over the HFNC. There was significant variation between the 2 participants, but in neither case was there a difference compared to control. There was an aerosol‐time trend, but there does not appear to be a difference between either flow rate, pressure, or control. Furthermore, there was no accumulation of total aerosol particles over the total duration of the experiment in both HFNC and NIPPV conditions. CONCLUSIONS: HFNC and NIPPV did not increase aerosol production compared to 6 L/min by low‐flow nasal cannula in this experiment involving healthy volunteers. John Wiley and Sons Inc. 2020-06-10 /pmc/articles/PMC7280651/ /pubmed/32838370 http://dx.doi.org/10.1002/emp2.12152 Text en © 2020 The Authors. JACEP Open published by Wiley Periodicals LLC on behalf of the American College of Emergency Physicians. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Infectious Disease
Miller, David C.
Beamer, Paloma
Billheimer, Dean
Subbian, Vignesh
Sorooshian, Armin
Campbell, Beth Salvagio
Mosier, Jarrod M.
Aerosol risk with noninvasive respiratory support in patients with COVID‐19
title Aerosol risk with noninvasive respiratory support in patients with COVID‐19
title_full Aerosol risk with noninvasive respiratory support in patients with COVID‐19
title_fullStr Aerosol risk with noninvasive respiratory support in patients with COVID‐19
title_full_unstemmed Aerosol risk with noninvasive respiratory support in patients with COVID‐19
title_short Aerosol risk with noninvasive respiratory support in patients with COVID‐19
title_sort aerosol risk with noninvasive respiratory support in patients with covid‐19
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280651/
https://www.ncbi.nlm.nih.gov/pubmed/32838370
http://dx.doi.org/10.1002/emp2.12152
work_keys_str_mv AT millerdavidc aerosolriskwithnoninvasiverespiratorysupportinpatientswithcovid19
AT beamerpaloma aerosolriskwithnoninvasiverespiratorysupportinpatientswithcovid19
AT billheimerdean aerosolriskwithnoninvasiverespiratorysupportinpatientswithcovid19
AT subbianvignesh aerosolriskwithnoninvasiverespiratorysupportinpatientswithcovid19
AT sorooshianarmin aerosolriskwithnoninvasiverespiratorysupportinpatientswithcovid19
AT campbellbethsalvagio aerosolriskwithnoninvasiverespiratorysupportinpatientswithcovid19
AT mosierjarrodm aerosolriskwithnoninvasiverespiratorysupportinpatientswithcovid19